COMMUNIQUÉS West-GlobeNewswire

-
Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025
21/10/2025 -
CorVel Corporation to Host Live Earnings Release Webcast
21/10/2025 -
Lighthouse Autism Center Appoints Joseph Giles as Chief Executive Officer and Chair of the Board
21/10/2025 -
Revium Rx Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections
21/10/2025 -
Dermsquared Appoints April Armstrong, MD, MPH, as Editor-in-Chief of the Dermatology Online Journal
21/10/2025 -
Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
21/10/2025 -
KFSHRC réalise la première résection robotisée au monde d’une tumeur intracrânienne... Une nouvelle ère en neurochirurgie
21/10/2025 -
Alignment Health Plan Joins Forces with Suvida Healthcare to Expand Bilingual Care, Access for Arizona Seniors
21/10/2025 -
RadNet to Host Investor Day on November 11, 2025
21/10/2025 -
RYBREVANT®▼ par voie sous-cutanée (amivantamab) offre un taux de réponse global prometteur de 45 pour cent associé à une durée de réponse médiane de 7,2 mois dans le cancer de la tête et du cou récurrent ou métastatique
21/10/2025 -
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
21/10/2025 -
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
21/10/2025 -
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
21/10/2025 -
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
21/10/2025 -
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
21/10/2025 -
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025
21/10/2025 -
Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
21/10/2025 -
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
21/10/2025 -
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
21/10/2025
Pages